Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar-Apr;38(2):980-986.
doi: 10.1111/jvim.16990. Epub 2024 Jan 11.

Development of a requirement for exogenous insulin treatment in dogs with hyperglycemia

Angielee DiNinni  1 , Rebecka S Hess  1
Affiliations

Development of a requirement for exogenous insulin treatment in dogs with hyperglycemia

Angielee DiNinni et al. J Vet Intern Med. 2024 Mar-Apr.

Abstract

Background: It has been suggested that overt diabetes mellitus in dogs be defined based on a persistent fasting blood glucose concentration (BGC) >144 mg/dL.

Objective: Determine the number of dogs with randomly identified hyperglycemia without insulin-treated diabetes mellitus (ITDM) that later develop a need for exogenous insulin treatment.

Animals: A total of 1318 dogs examined at a university teaching hospital without ITDM and with randomly identified hyperglycemia.

Methods: Retrospective longitudinal study. Hyperglycemia was defined as randomly identified BGC above >112 mg/dL, moderate hyperglycemia as BGC >144 mg/dL but <200 mg/dL and pronounced hyperglycemia as BGC ≥200 mg/dL. Dogs were defined as having ITDM if they were treated with insulin. Follow-up was attempted 7 to 12 years after hyperglycemia was documented to determine if over time dogs developed a need for exogenous insulin treatment.

Results: Twenty-nine of 824 dogs (3.5%) with hyperglycemia and follow-up information developed ITDM, including 3/824 dogs (0.4%) with moderate hyperglycemia, and 2/824 dogs (0.2%) with pronounced hyperglycemia. Most dogs with hyperglycemia that developed ITDM (24/29, 83%) had BGC ≤144 mg/dL. Among dogs that eventually developed a need for exogenous insulin treatment, no association was found between the degree of hyperglycemia and the time interval between documentation of hyperglycemia and diagnosis of ITDM. Logistic regression determined that BGC is not significantly associated with ITDM.

Conclusions and clinical importance: Most dogs with randomly identified hyperglycemia did not develop a need for exogenous insulin treatment. Other criteria could be required to augment the definition of overt DM in non-insulin treated dogs.

Keywords: canine; diabetes mellitus; diabetic; glucocorticoids; hyperadrenocorticism; steroids.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
The number and description of blood glucose samples and dogs screened and included in the study. BGC, blood glucose concentration.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gilor C, Niessen SJ, Furrow E, et al. What's in a name? Classification of diabetes mellitus in veterinary medicine and why it matters. J Vet Intern Med. 2016;30(4):927‐940. doi:10.1111/jvim.14357 - DOI - PMC - PubMed
    1. Niessen SJM, Bjornvad C, Church DB, et al. Agreeing language in veterinary endocrinology (ALIVE): diabetes mellitus – a modified Delphi‐method‐based system to create consensus disease definitions. Vet J. 2022;29(289):105910. doi:10.1016/j.tvjl.2022.105910 - DOI - PubMed
    1. American Diabetes Association . c1995‐2023 [Internet]. https://diabetes.org/diabetes/a1c/diagnosis
    1. Zeng Y, Ricordi C, Lendoire J, et al. The effect of prednisone on pancreatic islet autografts in dogs. Surgery. 1993;113(1):98‐102. - PMC - PubMed
    1. Heeley AM, Brodbelt DC, O'Neill DG, Church DB, Davison LJ. Assessment of glucocorticoid and antibiotic exposure as risk factors for diabetes mellitus in selected dog breeds attending UK primary‐care clinics. Vet Rec. 2023;2:e2785. doi:10.1002/vetr.2785 - DOI - PMC - PubMed